Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.69 |
| ▸ | MEN1 | O00255 | 8/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13407750 | 0.90 | MAPT (0.75) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL18826078 | 0.89 | KMT2A (0.76) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL13407754 | 0.88 | KDM4E (0.70) | ALDH1A1KMT2AMEN1POLBMAPT | |
| SCHEMBL13440499 | 0.86 | ALDH1A1 (0.74) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL20228785 | 0.83 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL13407763 | 0.82 | KMT2A (1.00) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL20228787 | 0.81 | ALDH1A1 (0.70) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL13407764 | 0.80 | POLB (1.00) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL13407759 | 0.79 | ALDH1A1 (0.78) | ALDH1A1KMT2AMEN1LMNAPOLB | |
| SCHEMBL5805462 | 0.79 | KDM4E (0.71) | ALDH1A1KMT2AMEN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | claimed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| EP-4171534-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL Business Ltd (GB) | 2023-05-03 | — | — | EP | claimed |
| EP-4665334-A1 | TRIPLE KINASE INHIBITION FOR THE TREATMENT OF TYPE I INTERFERON RESPONSE ASSOCIATED DISORDERS | Universität zu Köln (DE) | 2025-12-24 | — | — | EP | disclosed |
| CN-120018780-A | Hybrid process for producing complex HMO | 帝斯曼知识产权资产管理有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-111655258-B | Compositions for cryopreservation and methods of use thereof | 常青树生物科学公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | disclosed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| WO-2024197097-A2 | COMPOSITIONS AND METHODS UTILIZING NOVEL MECHANISMS TARGETING CELL RESPONSES TO STRESS | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20150359888-A1 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject | PALO ALTO INVESTORS | 2015-12-17 | — | — | US | disclosed |
| US-20140066466-A1 | Necroptosis Inhibitors and Methods of Use Therefor | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066466-A1 | Necroptosis Inhibitors and Methods of Use Therefor | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140024662-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2014-01-23 | — | — | US | disclosed |
| US-20140024662-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (CN) | 2014-01-23 | — | — | US | disclosed |
| WO-2012125544-A2 | NECROPTOSIS INHIBITORS AND METHODS OF USE THEREFOR | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20100087453-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066466-A1 | Necroptosis Inhibitors and Methods of Use Therefor | CD40, CD40LG, TNF | ALDH1A1 4779/4885KMT2A 4169/4885MEN1 3527/4885 |
| US-20140024662-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | ASAH2, LITAF, CYP27A1 | ALDH1A1 1140/4885KMT2A 4813/4885MEN1 2053/4885 |
| US-20100087453-A1 | COMPOUNDS, SCREENS, AND METHODS OF TREATMENT | ASAH2, LITAF, CYP27A1 | ALDH1A1 1121/4885KMT2A 4822/4885MEN1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.